Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT for Treatment of ADHD in Patients 6 Years and Older

By: via Benzinga
Neos Therapeutics, Inc. (Nasdaq: NEOS) today announced that the U.S. Food and Drug Administration (FDA) approved Adzenys XR-ODT™ for the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.